Sort   by:  
 Page size 
UnknownLiberal or restrictive transfusion in high-risk patients after hip surgery.
Not available
S-EPMC3268062 | biostudies-literature
UnknownBroad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
Not available
S-EPMC10159263 | biostudies-literature
UnknownCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904 | biostudies-literature
UnknownIFITM3 restricts the morbidity and mortality associated with influenza.
Not available
S-EPMC3648786 | biostudies-literature
UnknownSafety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Not available
S-EPMC9084623 | biostudies-literature
UnknownSafety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Not available
S-EPMC7674972 | biostudies-literature
UnknownSafety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Not available
S-EPMC8639161 | biostudies-literature
UnknownSafety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Not available
S-EPMC7723445 | biostudies-literature
UnknownPrediction of disability-free survival in healthy older people.
Not available
S-EPMC9213595 | biostudies-literature
UnknownPrespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT).
Not available
S-EPMC4898313 | biostudies-literature
Sort   by:  
 Page size